[ORGANIZATION]
JAMA Ophthalmology
Featured in 2 tracked stories · first seen
Situations
EssilorLuxottica optical technology developments
2 clusters · 4 sources · last updated
Latest: Essilor Stellest lenses slow myopia progression by 71% in US trial
EssilorLuxottica is managing divergent developments regarding its optical technologies. The company has received FDA De-Novo authorization in the United States for Stellest lenses, which are designed to slow myopia progr
Also covered in
-
EFEMP1 gene variants identified as cause of distinct vision loss
[HEALTH] · 2 sources ·